{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:52:02Z","timestamp":1778356322093,"version":"3.51.4"},"reference-count":22,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Samsung Bioepis Co., Ltd"},{"name":"SFL Regulatory Affairs and Scientific Communications Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>SB16 is a proposed biosimilar to reference denosumab (DEN; brand name: Prolia).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This phase 3 randomized, double-blind, multicenter study evaluated the biosimilarity of SB16 to DEN in women with postmenopausal osteoporosis (NCT04664959).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>The study included 457 postmenopausal osteoporosis patients who had a lumbar spine or total hip T-score between \u22122.5 and \u22124. Patients were randomized in a 1:1 ratio to receive either 60\u2005mg of SB16 or DEN subcutaneously at month 0 and month 6. At month 12, patients were rerandomized to continue with the assigned treatment or switch from DEN to SB16 up to month 18. This report includes results up to month 12.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The primary endpoint was the percent change from baseline in lumbar spine bone mineral density (BMD) at month 12. Secondary endpoints including the percent change from baseline in BMD of the lumbar spine (except for month 12), total hip, and femoral neck; pharmacokinetic, pharmacodynamic (serum C-telopeptide of type I collagen, and procollagen type I N-terminal propeptide), safety, and immunogenicity profiles were measured up to month 12.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The least-squares mean differences in percent change from baseline in lumbar spine BMD at month 12 were 0.33% (90% CI, \u22120.25 to 0.91) in the full analysis set and 0.39% (95% CI, \u22120.36 to 1.13) in the per-protocol set; both within the predefined equivalence margin. The secondary endpoints were comparable between the 2 treatment groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The reported efficacy, pharmacokinetic, pharmacodynamic, safety, and immunogenicity data support the biosimilarity of SB16 to DEN.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae611","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T16:38:48Z","timestamp":1725727128000},"page":"e1951-e1958","source":"Crossref","is-referenced-by-count":11,"title":["Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12"],"prefix":"10.1210","volume":"110","author":[{"given":"Bente","family":"Langdahl","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University , Aarhus, 8200 ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Sok","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Ajou University School of Medicine , Suwon, 16499 ,","place":["Republic of Korea"]},{"name":"Institute on Aging, Ajou University Medical Center , Suwon, 16499 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafal","family":"Plebanski","sequence":"additional","affiliation":[{"name":"Department of Clinic of Healthy Bone, Klinika Zdrowej Kosci , Lodz, 91-843 ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Czerwinski","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, Krakowskie Centrum Medyczne , Krakow, 31-501 ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Dokoupilova","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, MEDICAL PLUS sro , Uherske Hradiste, 686 01 ,","place":["Czech Republic"]},{"name":"Faculty of Pharmacy, Department of Pharmaceutical Technology, Masaryk University , Brno, 612 00 ,","place":["Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Supronik","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, OsteoMedic sc A Racewicz J Supronik , Bialystok, 15-351 ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Rosa","sequence":"additional","affiliation":[{"name":"Osteocenter, Affidea Praha, s.r.o. , Praha, 148 00 ,","place":["Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Mydlak","sequence":"additional","affiliation":[{"name":"Medical Department, ETG Siedlce , Siedlce, 08-110 ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Rowi\u0144ska-Osuch","sequence":"additional","affiliation":[{"name":"Department of Clinical Trials, ETG Warszawa , Warszawa, 02-677 ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Hyun","family":"Baek","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea , Seoul, 07345 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrone","family":"Urboniene","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, JSC Saules seimos medicinos centras , Kaunas, 49449 ,","place":["Lithuania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Mordaka","sequence":"additional","affiliation":[{"name":"Department of Santa Familia PTG Lodz, Santa Sp. z o.o. , Lodz, 90-302 ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohui","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Biometrics, Samsung Bioepis Co., Ltd. , Incheon, 21987 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hee","family":"Rho","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Samsung Bioepis Co., Ltd. , Incheon, 21987 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0786-5994","authenticated-orcid":false,"given":"Jisuk","family":"Ban","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Samsung Bioepis Co., Ltd. , Incheon, 21987 ,","place":["Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-3366","authenticated-orcid":false,"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine, University of Sheffield , Sheffield S10 2RX ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"issue":"405","key":"2025052712565864800_dgae611-B1","first-page":"1","article-title":"Osteoporosis or low bone mass in older adults: United States, 2017-2018","author":"Sarafrazi","year":"2021","journal-title":"NCHS Data Brief"},{"issue":"1","key":"2025052712565864800_dgae611-B2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0002-9343(91)90512-v","article-title":"Consensus development conference: prophylaxis and treatment of osteoporosis","volume":"90","year":"1991","journal-title":"Am J Med"},{"key":"2025052712565864800_dgae611-B3","author":"European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)","year":"2006"},{"issue":"5","key":"2025052712565864800_dgae611-B4","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2025052712565864800_dgae611-B5","author":"European Medicines Agency (EMA)","year":"2023"},{"key":"2025052712565864800_dgae611-B6","author":"US Food and Drug Administration (FDA)","year":"2024"},{"key":"2025052712565864800_dgae611-B7","author":"US Food and Drug Administration (FDA)","year":"2024"},{"key":"2025052712565864800_dgae611-B8","author":"European Medicines Agency (EMA) and European Commission (EC)","year":"2019"},{"key":"2025052712565864800_dgae611-B9","author":"European Medicines Agency (EMA)","year":"2015"},{"key":"2025052712565864800_dgae611-B10","author":"United States Food and Drug Administration (FDA)","year":"2015"},{"issue":"11","key":"2025052712565864800_dgae611-B11","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1359\/jbmr.1997.12.11.1761","article-title":"Prevalence of low femoral bone density in older U.S. Adults from NHANES III","volume":"12","author":"Looker","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025052712565864800_dgae611-B12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025052712565864800_dgae611-B13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"2025052712565864800_dgae611-B14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2025052712565864800_dgae611-B15","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025052712565864800_dgae611-B16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment","volume":"34","author":"Ferrari","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025052712565864800_dgae611-B17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025052712565864800_dgae611-B18","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00198-019-05020-8","article-title":"Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM extension cross-over group","volume":"30","author":"Bilezikian","year":"2019","journal-title":"Osteoporos Int"},{"issue":"8","key":"2025052712565864800_dgae611-B19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2025052712565864800_dgae611-B20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2023","journal-title":"Endocr Rev"},{"issue":"2","key":"2025052712565864800_dgae611-B21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jbmr.4178","article-title":"Treatment-Related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: proportion of treatment effect explained","volume":"36","author":"Eastell","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025052712565864800_dgae611-B22","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jbmr.3355","article-title":"Treatment-Related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression","volume":"33","author":"Bauer","year":"2018","journal-title":"J Bone Miner Res"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae611\/59458883\/dgae611.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/6\/e1951\/59458883\/dgae611.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/6\/e1951\/59458883\/dgae611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:57:47Z","timestamp":1748365067000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/6\/e1951\/7750697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,9,7]]},"published-print":{"date-parts":[[2025,5,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae611","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,9,7]]}}}